Clinical trials: FLU
Influenza, Pneumonia
Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years
The overall objective of this study is to describe the effectiveness of Flublok Quadrivalent vaccine compared to standard dose inactivated influenza vaccine (SD-IIV) in adults 18 through 64 years of age.
- Conditions
- Influenza, Pneumonia, Lower Respiratory Tract Infection, Acute Myocardial Infarction
- Trial name
- NCT03694392
- Testing
- Flublok Quadrivalent, Standard Dose Inactivated Influenza Vaccine (SD-IIV)
- Where
- United States
- Volunteers
- 2,776,278 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Influenza
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly
The objective of the study is to evaluate immunogenicity between different formulations of GSK Biologicals' investigational vaccine GSK2186877A.
- Trial name
- NCT00938392
- Testing
- GSK investigational FluNG vaccine GSK2186877A, aged lot, GSK investigational FluNG vaccine GSK2186877A, fresh lot
- Where
- 6 sites in Estonia, Slovakia
- Volunteers
- 726 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Vaccination
Encouraging Flu Vaccination Among High-Risk Patients Identified by ML
The purpose of the current study is to test different interventions to determine the most effective way to promote flu vaccine uptake in a high-risk population identified by an "artificial intelligence" (AI) or machine learning…
- Conditions
- Influenza, Vaccination, Health Promotion, Health Behavior
- Trial name
- NCT04323137
- Testing
- Risk reduction, Medical records-based recommendation, Algorithm-based recommendation
- Where
- United States
- Volunteers
- 117,649 people
- Sponsor
- Geisinger Clinic
Influenza
Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.
This is a study for patients with flu who also have a fever as well as other flu symptoms. Patients must have had symptoms for less than 48 hours in order to participate.
- Trial name
- NCT00419263
- Testing
- Peramivir 150 mg, Peramivir 300 mg
- Where
- 69 sites in United States, Canada
- Volunteers
- 344 people
- Sponsor
- BioCryst Pharmaceuticals
Healthy
Acute Respiratory Illness Surveillance (AcRIS) With Mobile Application in a Low-Interventional Decentralized Study.
The purpose of the AcRIS study is to obtain data to characterize the relationship between symptoms and voice features for (reverse transcription polymerase chain reaction (RT-PCR) confirmed severe acute respiratory syndrome…
- Trial name
- NCT04748445
- Testing
- SARS-CoV-2/Influenza/RSV RT-PCR
- Where
- United States
- Volunteers
- 9,151 people, healthy volunteers welcome
- Sponsor
- Pfizer
Upper Respiratory Tract Infection, Nasal Congestion
Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu
The study is a clinical evaluation of an over the counter (OTC) combination product containing paracetamol (500 mg), dimethindene maleate (1 mg), phenylephrine hydrochloride (10 mg) compared to paracetamol (500 mg) alone in the…
- Conditions
- Upper Respiratory Tract Infection, Nasal Congestion, Rhinorrhea, Sneezing
- Trial name
- NCT01448057
- Testing
- Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets, Paracetamol (500 mg) tablets
- Where
- 6 sites in Brazil
- Volunteers
- 341 people
- Sponsor
- Novartis
Cancer
Safety Study to Evaluate FluMist in Immunocompromised Children
The main purpose of this study is to get information about the safety of a flu vaccine spray, called FluMist, in children with cancer.
- Trial name
- NCT00112112
- Testing
- FluMist
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- MedImmune LLC
Influenza
Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
This is a randomized clinical trial designed to evaluate the safety/efficacy of two dosing regimens of oral nitazoxanide compared to placebo in the treatment of acute uncomplicated influenza in adults and adolescents.
- Trial name
- NCT01227421
- Testing
- Nitazoxanide
- Where
- United States
- Volunteers
- 624 people
- Sponsor
- Romark Laboratories L.C.
Influenza, Human
A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years
The purpose of this study is to assess the reactogenicity, safety and immunogenicity of different formulations of GlaxoSmithKline (GSK) Biologicals' investigational supra-seasonal universal influenza vaccines (SUIVs)…
- Trial name
- NCT03275389
- Testing
- D-SUIV cH8/1N1+AS03, D-SUIV cH5/1N1+AS03, D-SUIV cH11/1N1+AS03
- Where
- 6 sites in United States, Belgium
- Volunteers
- 470 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older
This clinical trial aims to study the immunogenicity of GSK Biologicals' influenza vaccine GSK2186877A in people aged 65 years or older.
- Trial name
- NCT00765076
- Testing
- GSK Biologicals' influenza vaccine GSK2186877A, GSK Biologicals' Fluarix
- Where
- 4 sites in United States, Spain
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Behavior, Health, Flu
Behavioral Economics to Improve Flu Vaccination Using EHR Nudges Replication
This study will be a 6-month, cluster randomized, pragmatic replication trial to evaluate the effectiveness of personalized nudges to clinicians and patients, relative to a control, to increase flu vaccination rates among older…
- Conditions
- Behavior, Health, Flu, Flu Vaccination
- Trial name
- BE IMMUNE Rep (NCT06626321)
- Testing
- Pre-visit patient text messaging, Default pended order, Monthly peer comparison feedback
- Where
- United States
- Volunteers
- 26,248 people
- Sponsor
- University of Pennsylvania
Influenza
Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/CALIFORNIA/66/395 (H2N2) Influenza Vaccine
This is a phase I study to evaluate the safety of a vaccine to protect against influenza viruses of the H2N2 subtype. A total of 40 adults will be enrolled and receive two doses of vaccine or placebo one month apart.
- Trial name
- NCT01982331
- Testing
- LAIV H2N2
- Where
- Russia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- PATH
Influenza
Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)
The purpose of this study is to investigate the responses to licensed trivalent, inactivated influenza vaccine (TIV) delivered by different routes: intramuscular (IM) and intradermal (ID) and to the live, attenuated influenza…
- Trial name
- NCT02141581
- Testing
- Fluzone® (IM), Fluzone® Intradermal (ID), 2011-2012 FluMist®
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza
Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children
The purpose of this study is to evaluate the immunogenicity and the safety of GlaxoSmithKline Biologicals' seasonal influenza vaccine, Fluarix, compared to Fluzone (a US-licensed vaccine) in children, 6 to 35 months of age.
- Trial name
- NCT00764790
- Testing
- Fluarix, Fluzone
- Where
- 69 sites in United States, Hong Kong and 3 more
- Volunteers
- 3,317 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immune Response Following Seasonal Influenza Vaccination
This is an open-label, single administration dose study in adult healthy male and female subjects. After qualifying for the study, subjects will receive a single intramuscular injection of the FDA approved 2016-2017 quadrivalent…
- Trial name
- NCT03163342
- Testing
- Licensed seasonal influenza vaccine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
Influenza
Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults
Since influenza vaccines are administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of GSK Biologicals' influenza vaccine GSK576389A will be re-evaluated after…
- Trial name
- NCT00529516
- Testing
- Fluarix, GSK Biologicals Influenza Vaccine GSK576389A
- Where
- 29 sites in United States, Belgium and 2 more
- Volunteers
- 1,252 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acute Respiratory Viral Infections, Human Influenza
Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.
This randomized, single blind clinical study was conducted to investigate the clinical efficacy and safety of the drug Amizon (enisamium iodide), in comparison with placebo for the treatment of patients with acute respiratory…
- Trial name
- NCT04682444
- Testing
- Enisamium Iodide
- Volunteers
- 100 people
- Sponsor
- Joint Stock Company "Farmak"
Influenza
A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza
The purpose of this study is to evaluate safety and tolerability of a single dose of MEDI8852 when given with oseltamivir, the safety and tolerability of oseltamivir alone, and the safety and tolerability of a single dose of…
- Trial name
- MEDI8852 (NCT02603952)
- Testing
- Oseltamivir, MEDI8852
- Where
- 31 sites in United States, South Africa
- Volunteers
- 126 people
- Sponsor
- MedImmune LLC
Rheumatoid Arthritis
Standard Versus High Dose Inactivated Influenza Vaccine in RA
Patients with rheumatoid arthritis have increased risk of seasonal influenza and influenza-related complications but have reduced vaccine immunogenicity.
- Trial name
- IV-RA (NCT02936180)
- Testing
- HD-TIV, SD-QIV
- Where
- Canada
- Volunteers
- 279 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Influenza
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
This randomized, modified double-blind, active-controlled, multi-center trial assessed the safety and immunogenicity of the high-dose quadrivalent influenza vaccine (QIV-HD) compared to either the licensed or investigational…
- Trial name
- NCT03282240
- Testing
- QIV-HD, Licensed TIV-HD1, Investigational TIV-HD2
- Where
- 36 sites in United States
- Volunteers
- 2,670 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company